

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371U.S. APPLICATION NO. (If Known, see 37 CFR
1.5) 09/936452INTERNATIONAL APPLICATION NO.
PCT/AU00/00180INTERNATIONAL FILING DATE
10 March 2000PRIORITY DATE CLAIMED
11 March 1999

TITLE OF INVENTION

SAMPLE COLLECTION AND TESTING SYSTEM

APPLICANT(S) FOR DO/EO/US

Howard Milne Chandler and Lawrence Charles La Pointe

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other documents or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:
 - Copy of PCT/AU00/00180 as published 14 Sept. 2000
 - Copy of PCT/IB/308
 - Copy of International Preliminary Examination Report
 - Copy of PCT/IPEA/402
 - Acknowledgement Postcard

CERTIFICATE OF MAILING BY EXPRESS MAIL




Express Mail Label No EL 228026621 US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D C 20231

September 12, 2001
Date of Deposit

Signature

Samantha Bell
Typed Name of
Person Signing

U.S. APPLICATION NO. (IF KNOWN) 08/936452		INTERNATIONAL APPLICATION NO. PCT/AU00/00180	ATTORNEY'S DOCKET NUMBER 13521-002001																																																																						
<input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100		CALCULATIONS PTO USE ONLY																																																																							
ENTER APPROPRIATE BASIC FEE AMOUNT = <input type="text" value="1,000.00"/>																																																																									
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="text" value="\$130.00"/>																																																																									
<table border="1"> <thead> <tr> <th>Claims</th> <th>Number Filed</th> <th>Number Extra</th> <th>Rate</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>23 - 20 =</td> <td>3</td> <td>x \$18</td> </tr> <tr> <td>Independent Claims</td> <td>2 - 3 =</td> <td>0</td> <td>x \$80</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIMS(S) (if applicable)</td> <td></td> <td>+ \$270</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS = <input type="text" value="\$1,184.00"/></td> </tr> <tr> <td colspan="4"> <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. <input type="text" value="\$0.00"/> </td> </tr> <tr> <td colspan="4"> SUBTOTAL = <input type="text" value="\$1,184.00"/> </td> </tr> <tr> <td colspan="4"> Processing fee of \$130 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) <input type="text" value="\$0.00"/> </td> </tr> <tr> <td colspan="4"> TOTAL NATIONAL FEE = <input type="text" value="1,184.00"/> </td> </tr> <tr> <td colspan="4"> Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + <input type="text" value="\$0.00"/> </td> </tr> <tr> <td colspan="4"> TOTAL FEES ENCLOSED = <input type="text" value="1,184.00"/> </td> </tr> <tr> <td colspan="2" rowspan="2"></td> <td>Amount to be refunded:</td> <td>\$</td> </tr> <tr> <td>Charged:</td> <td>\$</td> </tr> <tr> <td colspan="4"> a. <input checked="" type="checkbox"/> A check in the amount of \$1,184.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed. </td> </tr> <tr> <td colspan="4"> NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status. </td> </tr> <tr> <td colspan="4"> SEND ALL CORRESPONDENCE TO:  Janis K. Fraser, Ph.D., J.D. FISH & RICHARDSON P.C. 225 Franklin Street Boston, Massachusetts 02110-2804 (617) 542-5070 phone (617) 542-8906 facsimile </td> </tr> <tr> <td colspan="2"> SIGNATURE: <input type="text" value="Janis K. Fraser, Ph.D., J.D."/> </td> <td colspan="2"> NAME: <input type="text" value="Janis K. Fraser, Ph.D., J.D."/> </td> </tr> <tr> <td colspan="2"></td> <td colspan="2"> REGISTRATION NUMBER: <input type="text" value="34,819"/> </td> </tr> </tbody></table>				Claims	Number Filed	Number Extra	Rate	Total Claims	23 - 20 =	3	x \$18	Independent Claims	2 - 3 =	0	x \$80	MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270	TOTAL OF ABOVE CALCULATIONS = <input type="text" value="\$1,184.00"/>				<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. <input type="text" value="\$0.00"/>				SUBTOTAL = <input type="text" value="\$1,184.00"/>				Processing fee of \$130 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) <input type="text" value="\$0.00"/>				TOTAL NATIONAL FEE = <input type="text" value="1,184.00"/>				Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + <input type="text" value="\$0.00"/>				TOTAL FEES ENCLOSED = <input type="text" value="1,184.00"/>						Amount to be refunded:	\$	Charged:	\$	a. <input checked="" type="checkbox"/> A check in the amount of \$1,184.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.				NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.				SEND ALL CORRESPONDENCE TO:  Janis K. Fraser, Ph.D., J.D. FISH & RICHARDSON P.C. 225 Franklin Street Boston, Massachusetts 02110-2804 (617) 542-5070 phone (617) 542-8906 facsimile				SIGNATURE: <input type="text" value="Janis K. Fraser, Ph.D., J.D."/>		NAME: <input type="text" value="Janis K. Fraser, Ph.D., J.D."/>				REGISTRATION NUMBER: <input type="text" value="34,819"/>	
Claims	Number Filed	Number Extra	Rate																																																																						
Total Claims	23 - 20 =	3	x \$18																																																																						
Independent Claims	2 - 3 =	0	x \$80																																																																						
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270																																																																						
TOTAL OF ABOVE CALCULATIONS = <input type="text" value="\$1,184.00"/>																																																																									
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. <input type="text" value="\$0.00"/>																																																																									
SUBTOTAL = <input type="text" value="\$1,184.00"/>																																																																									
Processing fee of \$130 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) <input type="text" value="\$0.00"/>																																																																									
TOTAL NATIONAL FEE = <input type="text" value="1,184.00"/>																																																																									
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + <input type="text" value="\$0.00"/>																																																																									
TOTAL FEES ENCLOSED = <input type="text" value="1,184.00"/>																																																																									
		Amount to be refunded:	\$																																																																						
		Charged:	\$																																																																						
a. <input checked="" type="checkbox"/> A check in the amount of \$1,184.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.																																																																									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.																																																																									
SEND ALL CORRESPONDENCE TO:  Janis K. Fraser, Ph.D., J.D. FISH & RICHARDSON P.C. 225 Franklin Street Boston, Massachusetts 02110-2804 (617) 542-5070 phone (617) 542-8906 facsimile																																																																									
SIGNATURE: <input type="text" value="Janis K. Fraser, Ph.D., J.D."/>		NAME: <input type="text" value="Janis K. Fraser, Ph.D., J.D."/>																																																																							
		REGISTRATION NUMBER: <input type="text" value="34,819"/>																																																																							

SAMPLE COLLECTION AND TESTING SYSTEM

FIELD OF THE INVENTION

5

This invention relates to an apparatus and method for the collection and testing of a sample to detect an analyte in the sample, particularly but not exclusively by immunodiagnostic testing. The format of the collection and testing system of the present invention is particularly useful for ascertaining the health status of a human or 10 other animal or a plant or other life form, or the environmental status of a geographical or industrial location by ascertaining the presence or absence of an analyte in a sample. Although useful for immediate sample application and test development, the format is particularly applicable in those circumstances where the sample is collected at one site for test development at another location.

15

BACKGROUND OF THE INVENTION

A variety of diagnostic devices have been developed for the detection of an analyte of interest in a sample. In those devices in which sample collection and testing 20 functions are non-linked, the transfer of collected sample to testing apparatus introduces a potential source of error. In those devices in which sample collection and testing functions are linked, the devices are dedicated in their entirety to the detection of a particular analyte and are not easily adaptable to a wide range of analyte detection.

25

With respect to mammalian systems (e.g. humans), samples amenable to analysis using the testing device of the present invention include biological fluids (e.g. blood, urine, semen, saliva, etc.) or excrements. Such biological fluids can carry a variety of analytes, the presence of which can be diagnostic for a particular disease 30 state. The application of the subject invention to the detection of disease states in

humans is of primary importance. However, in addition to use in the context of the diagnosis of serious disease states, the present invention is also useful in a variety of other contexts. Applications in connection with the analysis of microbes, plants, animals, food and water are all anticipated.

5

For example, ground water samples can be analysed for the presence of contaminants such as atrazine. Food, such as ground beef, can be analysed for the presence of contamination by bacteria such as *E. coli*. In the plant kingdom, the present invention can be applied to the analysis of, for example, pollen, spores and 10 plant vascular fluids. Generally speaking, the only requirement for detection using the device and method of the present invention is that the analyte of interest should be soluble or suspendible in an aqueous solution.

The present invention relates to a device which is useful *inter alia* for the 15 detection of any aqueous soluble or suspendible analyte which is detectable, for example, on the basis of immunological and/or chemical properties. An example of an analyte detected by its immunological properties includes, but is not limited to, an immune interacting molecule such as an antigen, hapten, immunoglobulin or T-cell derived antigen binding molecule. An example of an analyte detected by chemical 20 properties includes an enzyme, catalyst or ligand. Thus, in detection of occult gastrointestinal bleeding as a screen for colo-rectal cancer, using the faecal occult blood (FOB) test, the device of the present invention can be adapted to either guaiac-based testing, or immunological testing. The preferred format for immunological testing is immunochromatography. This format is described generally 25 in U.S. Patent Nos. 5,591,645 and 5,622,871, the disclosures of which are incorporated herein by reference.

Prior to discussing the invention in greater detail, a brief review of the 30 immunochromatography process will be provided to establish certain principles. To detect an analyte of interest by immunochromatography, two binding reagents which

bind specifically and non-competitively to the analyte of interest may be employed. A first specific binding reagent is labelled and is free to migrate. When introduced to a sample to be tested for the presence of the analyte of interest, the first specific binding reagent binds to the analyte of interest, if present. The second specific binding reagent is immobilized in a detection zone on a liquid-conductive solid phase material, the detection zone being remote and downstream from the location of initial contact between the first binding reagent and the analyte of interest. A solvent front carrying the mobile first specific binding reagent complexed with analyte of interest (if present) migrates along the liquid-conductive solid phase material through the detection zone.

5

10 If analyte is present in the sample, the immobilised second specific binding reagent binds the analyte thereby forming an immobilised sandwich complex comprising the first specific binding reagent (which is labelled), the analyte of interest, and the second specific binding reagent (which is immobilised). Detection of the label immobilised in the detection zone is indicative of the presence of analyte of interest in the sample.

15 In most embodiments, the first and second specific binding reagents are either polyclonal or monoclonal antibodies.

Many diagnostic tests and assays involve the use of samples collected in the field and then either tested immediately, or returned to a central facility for later test development. Such samples may include blood, serum, saliva, milk, faeces, urine or other materials of biological origin, or samples collected from the environment, such as water for analysis for nutrients or contamination.

For example, in the practice of medicine, one or more blood samples may be drawn from a patient in the physician's office and then sent to a pathology laboratory for subsequent testing for one or more analytes. Typically the blood is drawn by venipuncture, using an especially designed needle and blood collection tube (e.g. Vacutainer, Becton Dickinson). The collection of the blood by venipuncture requires trained personnel, the provision of suitable facilities and equipment, refrigerated transport and storage facilities, and finally means for accurate sampling, treatment

(e.g. serum or plasma separation) and dispensing of the blood/plasma/serum into the test or assay equipment. In many cases the blood is only used for one test and, if an effective collection means were available, the blood from a finger prick would be sufficient.

5

Recently, there has been a marked increase in the use of "Point of Care" (POC) testing, using rapid, self-developing test systems packaged in simple, single-use, disposable test devices. Such POC tests include assays for glucose monitoring, pregnancy and infections such as Streptococcal infection of the throat and Chlamydia 10 infection of the genital tract. Many of these tests, however, introduce a limitation that the test must be conducted immediately at the test site, as the tests have been designed such that the addition of the sample initiates the test. In addition, these tests generally do not incorporate a sample collection system, but rely on the sample being obtained at the time of testing, or else being presented in a separate collection vessel, 15 such as a Vacutainer, as described above.

For many test systems, it is desirable for the sample to be tested to be collected at one site for subsequent test development at another site. In such instances, it is desirable to have a simple, inexpensive and safe means of delivering this testing 20 option, preferably by means of an integral collection and testing system.

Ideally, the prerequisites for such an integrated collection and test system would include:

25 • generic design, that is, one basic format to suit all test applications;
• simple, accurate and representative sampling, requiring minimal skills and equipment to collect the sample;
• safe, stable, and inexpensive storage of the sample;
• effective reconstitution and/or displacement of the sample to the testing means
30 for development of the test; and

- 5 -

- cost-effective delivery of the test result.

It is an object of the present invention to provide a test format that meets these requirements and is suited for the delivery of samples for either immediate or later 5 testing.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a device for use in the collection 10 and testing of a sample, comprising:

- a housing having an internal recess; and
- a sample collection device;

said housing being adapted to receive said sample collection device in the internal recess therein and to shield a sample collected on said sample collection device, said 15 housing also being adapted to receive an insertable testing element, such that on insertion of said testing element into said housing, the testing element is in liquid-conductive communication with a sample collected on said sample collection device.

In another aspect, the present invention provides a testing device for the 20 identification of an analyte of interest in a sample, comprising:

- a housing having an internal recess;
- a sample collection device; and
- at least one insertable testing element;

said housing being adapted to receive said sample collection device in the internal 25 recess therein and to shield a sample collected on said sample collection device, said housing also being adapted to receive the or each said insertable testing element such that, on insertion of said testing element into said housing, the testing element is in liquid-conductive communication with a sample collected on said sample collection device.

In another aspect, the present invention provides a method for the identification of an analyte of interest in a sample by use of a testing device as broadly described above, comprising:

- a. collecting a sample on the sample collection device,
- 5 b. inserting said sample collection device into the internal recess of the housing of the testing device,
- c. inserting the insertable testing element into the housing such that the testing element is in liquid-conductive communication with said sample, and optionally
- d. applying a solvent to said sample to enable transfer of at least part of said
- 10 sample, or a component thereof, to the testing element.

Throughout this specification, unless the context requires otherwise, the word "comprise", and or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not

15 the exclusion of any other integer or step or group of integers or steps.

DETAILED DESCRIPTION OF THE INVENTION

An important feature of the testing device of the present invention is that the

20 single device serves a collection and testing function. However, the testing function is not linked to collection of a sample. That is, the collection of a sample (e.g. by a patient in the home) and application to the testing device does not yield a test result. In order to determine the test result, an insertable testing element must be inserted into the device, and if the sample has previously been dried or desiccated the sample must

25 be rehydrated.

Preferably, the sample is a liquid containing sample. The sample may itself be a liquid or it may be in a particulate or solid form which is then hydrated prior to testing. In a preferred but not essential aspect of this invention, the testing device is adapted

30 so that a sample applied to the sample collection device (for example, by a patient in

the home) may be dried or desiccated on the sample collection device within the housing of the testing device.

In accordance with this invention, the testing element is adapted to be inserted 5 into the housing of the device so that the testing element is in liquid-conductive communication with the sample collection device as described above.

Preferably, the housing is provided with a first window or aperture communicating with the internal recess within the housing for insertion of the sample 10 collection device, together with at least one additional window or aperture which is separate from the first window or aperture and which also communicates with the internal recess for insertion of the, or each, insertable testing element so that the testing element is in liquid-conductive communication with a sample collected on said sample collection device.

15

As used herein, the term "liquid-conductive communication" shall be taken to mean that a solvent applied to a sample is capable of being in liquid-conductive communication with the testing element under sufficient conditions of hydration to enable transfer of at least part of said sample, or a component thereof, to the testing 20 element.

The three components of a preferred embodiment of the testing device of the present invention are:

25 1. a sample collection device designed to collect, and store, a predetermined (that is a quantified or semi-quantified) amount of sample,
2. a housing having an internal recess designed to accept and protect the sample collection device and, if required, offer sufficient ventilation to allow dehydration of a liquid sample collected on the sample collection
30 device, and

3. a testing element designed so that, on insertion into the housing, liquid-conductive contact is established with the sample collection device.

Each of the components is designed, or selected, for its suitability for
5 inexpensive, high-speed, automated manufacture by established manufacturing
technologies.

The sample collection device is designed to enable sample collection without
the requirement for laboratory facilities, equipment, or highly trained or skilled
10 personnel. For some applications, the collection device may be an existing device,
such as a swab. Other applications will require a custom designed device to
accurately meter, accept and store a predetermined amount of specimen. In many
cases, this component will consist of a hydrophilic, porous matrix, of defined volumetric
capacity, affixed to the base of a dipstick or handle, so that collection of a sample
15 involves touching the matrix to the sample, thus filling the matrix with a measured
volume of the sample. The preferred embodiment of the sample collection device
described herein is designed for manufacture by established high-speed laminating
and die-cutting processes.

20 The housing is also designed for manufacture by rapid packaging technologies,
such as "Form, Fill and Seal" technology. The housing has an internal recess which
serves to store and protect the sample, as well as facilitate the transfer of the sample
to the testing element at the time of test initiation. It may also house or receive any
reagents necessary for initiation or completion of the test procedure.

25

In many instances, the testing element will be an immunochromatographic test
strip, such as are used in numerous existing POC tests. Most of the existing tests,
however, have the test strip mounted in a housing so that the addition of the sample
initiates the development of the test. These tests are therefore not suitable for remote
30 sampling and centralised test development. In addition, the existing POC tests are

expensive to manufacture. The test strip and housing components must be assembled and then stored dry, as the reagents in the test strip are subject to rapid degradation in the presence of humidity. Desiccated packaging of significant cost and volume must therefore be provided. In accordance with the present invention, the test strip is 5 inserted into the housing at the time of testing, thus avoiding any assembly costs. These test strips may also be stored in bulk, for example in a desiccated container, thus saving on packaging and storage costs.

In another embodiment of the present invention, the testing device may 10 comprise two or more insertable testing elements each of which, when inserted, is in liquid-conductive communication with the sample collection device. In this embodiment, the testing elements may be either the same or they may be different. In the former case, replicate tests may be carried out on the sample applied to the sample collection device. In the latter case, different tests may be carried out on the 15 same sample applied to the sample application matrix. By way of example, in FOB testing for screening for colo-rectal cancer, one insertable testing element may be a guaiac-based test strip, whilst another insertable testing element may be an immunochromatographic test strip.

Given the description which follows, one of skill in the art will recognize that the 20 testing element or elements may be provided in an array of alternative embodiments. Referring to the immunochromatographic embodiment, for example, a required element of the test strip is a liquid-conductive solid phase material to which a detection reagent (described above in the brief review of immunochromatography as the second 25 specific binding reagent) may be immobilized. This solid phase material is preferably nitrocellulose. Nitrocellulose is a charged matrix to which an appropriately charged reagent, such as a monoclonal antibody, may be immobilized without prior chemical treatment. Alternatives such as filter paper may also be used, however, chemical coupling (e.g., CNBr coupling) is required to attach a charged reagent such as an 30 antibody to a matrix of this type.

09295462 2009-06-16 10:30:45

A preferred liquid-conductive solid phase material is a nitrocellulose membrane having a pore size of at least about 1 micron. Nitrocellulose membranes best adapted for use in connection for immunochromatography of this type have a pore size of about 5-20 microns. The selection of particular pore size dictates flow rate.

5 Depending upon the particular application, a faster or slower flow rate may be indicated and an appropriate solid phase material is selected.

To facilitate handling, it is desirable to provide a backing to the nitrocellulose membrane. A thin plastic sheet stock (e.g., lexan or polystyrene) may be cut to

10 provide a suitable water resistant backing for the solid support. Such sheet stock is selected so as not to interfere with the reading of a test result. For example, the selection of a white or clear sheet stock is generally preferred. In an alternative embodiment, the liquid conductive solid phase material may be sandwiched between such water resistant sheet stock.

15

When inserted into the housing, the or each testing element is designed to be in liquid-conductive communication with the sample collection device. Preferably, this liquid-conductive communication is direct, for example between the sample collection device and the liquid-conductive solid phase material of an immunochromatographic 20 or other testing element. In a preferred immunochromatography embodiment, additional liquid-conductive elements may be incorporated in or on the testing element. For example, a conjugate pad may be provided which, in use, is disposed between the sample collection device and the liquid-conductive solid phase material of the testing element. As will be discussed in greater detail below, the conjugate pad provides a 25 matrix for the deposition of a labelled detection reagent which is free to migrate when rehydrated (the first specific binding reagent in the brief review of immunochromatography provided above). The sample may be dehydrated or desiccated within the sample collection device prior to the insertion of the testing element. At the time of rehydration during the testing step, the labelled detection 30 reagent within the conjugate pad is also resuspended and resolubilised. If analyte is

present in the sample, the labelled reagent binds to the analyte and the complex is carried along with the solvent front to the detection zone of the testing element.

At the end of the testing element distal to the conjugate pad when in use, an

5 optional absorbent pad is attached, in communication with the liquid-conductive solid phase material. This pad provides a solvent sink which drives the migration of the liquid sample through the detection zone. It is important that the absorbent pad have sufficient volume to drive the migration to the extent that substantially all unbound labelled detection reagent is carried beyond the detection zone of the testing element.

10 One of skill in the art will recognize that an absorbent pad is a non-essential element. The need for this element can be obviated, for example, by extending the length of the liquid-conductive solid phase material beyond the detection zone such that a sufficient volume is carried through the detection zone.

15 In use, a sample is collected on the sample collection device in a conventional manner. For example, in FOB testing, a faecal smear may be collected on the sample collection device, or alternatively, toilet bowl water may be sampled using an absorbent swab. In the latter sampling method, a short time may be allowed for haemoglobin to diffuse from the stool prior to sampling, or the swab may be used as the sample

20 collection device to disperse the stool into the toilet bowl water. The swab is then used to sample the water.

Depending upon the nature of the analyte, the testing device with sample collection device inserted into the internal recess of the housing of the device may be

25 stored in this form for a period of days, weeks or months prior to testing. To determine the presence of an analyte, the sample is rehydrated by adding an appropriate solvent to the sample collection device. The solvent may be added through a solvent application aperture in the housing which is in communication with the sample collection device. Preferably, solvent applied through such a solvent application

30 aperture should migrate through the region of the sample collection device where

sample was actually applied, prior to reaching the point on the sample collection device which is in liquid-conductive communication with the testing element.

The labelled detection reagent may be introduced into the 5 immunochromatography assay in a variety of ways. For example, the labelled detection reagent may be solubilized in the solvent used to rehydrate the contents of the sample collection device prior to the resolubilisation of the sample or its components. Alternatively, as discussed above, the labelled detection reagent may be introduced in solution into the conjugate pad and desiccated *in situ*. In this 10 embodiment, the labelled detection reagent is resolubilized as the resolubilization solvent migrates from the sample collection device to the testing element. In yet another embodiment, a solution containing the labelled detection reagent may be added to the sample collection device prior to the application of the sample. This 15 solution is then desiccated *in situ*. In this embodiment, analyte of interest, if present, and labelled detection reagent will be solubilized from the dry sample collection device at the time of testing.

Of the embodiments described in the preceding paragraph, the use of a conjugate pad is preferred for most embodiments. The addition of the labelled 20 detection reagent to the resolubilization solvent prior to sample resolubilization has the disadvantage of using the expensive detection reagent (which could require storage at 4°C) in an inefficient manner. With respect to the desiccation *in situ* of the labelled detection reagent in the sample collection device prior to sample collection, this would result in the establishment of a testing device in which the sample collection device is 25 dedicated to a particular assay. One of the many benefits of the disclosed device is the fact that the housing (together with other elements of the device excluding the testing element) is totally generic. Thus, the housing of the testing device as well as the sample collection device can be purchased in bulk and stored as needed for any of a variety of testing requirements. The relatively expensive test-specific component is

the testing element which can be selected for a particular need and used in conjunction with the generic housing and sample collection device.

Preferably the labelled detection reagent is a monoclonal or polyclonal antibody 5 specific for a first epitope of the analyte of interest, coupled to a detectable label. The detectable label can be coupled to the antibody by any of the applicable techniques known in the art including, for example, covalent bonding and passive adsorption.

The detectable label may be a direct or an indirect label. A direct label is a label 10 which is readily visible in its natural state, either to the naked eye, or with the aid of optical devices. A label which is visible only in the presence of external stimulation, such as ultraviolet light, is also considered to be a direct label. Examples of direct labels include dye sols (e.g., colloidal carbon), metallic sols (e.g., gold and iron), fluorescent particles and coloured latex particles.

15 Indirect labels require the addition of one or more developing reagents, such as substrates, to facilitate detection. Such labels include, for example, enzymes such as alkaline phosphatase and horseradish peroxidase.

20 The immobilized capture reagent is also typically a monoclonal or polyclonal antibody which is specific for a second epitope or range of epitopes on the analyte of interest. Thus, analyte present in the sample, whether bound by the detection reagent or not, is bound by the immobilized binding reagent in the detection zone. In a case in 25 which a direct label is employed, a visible line appears on the liquid-conductive solid support as bound label accumulates in the detection zone. The appearance of this line may be diagnostic for the presence of analyte of interest in the sample.

An optional control zone can also be integrated into the testing element. The function of a control zone is to convey an unrelated signal to the user which indicates 30 only that the testing process is complete and that the binding interaction which results

in the detectable unrelated signal has taken place as expected. For example, the control zone may comprise an "anti-mouse" polyclonal antibody immobilized to the liquid-conductive solid phase material, preferably downstream of the detection zone.

Assuming that the detection reagent is a murine monoclonal antibody linked to a

5 detectable label, detection reagents not bound in the detection zone through a sandwich interaction involving the analyte of interest will ultimately bind in the control zone. In the absence of a signal in the detection zone, a control zone signal would indicate to the user that, for example, the sample contained nothing that resulted in general interference with an immunological assay. It can be imagined, for example,

10 that extremes of pH or salt concentration could result in general interference through conformational changes or physical destruction on one or more of the participants in the immunologically based interaction to be detected. The inclusion of a control zone functions to provide a degree of confidence with respect to such variables.

15 The analyte of interest is determined in advance to be one which is diagnostic of a particular condition. For example, in connection with FOB tests, the analyte of interest is preferably human hemoglobin. Other examples of analytes of interest are described below.

20 The method and apparatus of the present invention is applicable to detecting analytes in humans and other animals. Other animals include primates, livestock animals (e.g. cows, sheep, horses, donkeys, pigs), laboratory test animals (e.g. rabbits, mice, rats, guinea pigs, hamster), companion animals (e.g. dogs, cats) and captive wild animals. The present invention also extends to detecting analytes in

25 plants (e.g. monocotyledons and dicotyledons) and other life forms (e.g. microbes, yeasts, fungi, moulds). The present invention may also be used to detect analytes in geographic and industrial locations, including soil, oceans, rivers, water storage regions, toxic waste dumps, building sites, mining areas (e.g. coal, bauxite, uranium, graphite amongst many others) as well as in the air. The health status of humans, and

30 other animals or plants or other life forms may be deduced or determined in the

presence or level of analyte or by the absence of analyte. The environmental status may also be ascertained such as determining the presence of contaminants in various geographic or industrial locations.

5 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates a testing device in accordance with the present invention which is particularly adapted for use with samples or specimens collected on an absorbent swab.

10

Figure 2 illustrates an immunochromatographic test step for use in the testing device of the present invention.

15

Figure 3 illustrates an alternative sample collection device for use in the testing device of the present invention.

DESCRIPTION OF PREFERRED EMBODIMENTS

Figure 1 illustrates the testing device of the present invention in a format which 20 uses a swab as the sample collection device. A swab may be used as a general sampling device for many liquid or moist specimen types, provided that they do not require an accurately measured volume of sample. Swabs are frequently used for obtaining infectious clinical samples, for example for testing for *Streptococcus pyogenes* Type A (Strep.A) in cases of throat infection.

25

The current POC tests for Strep.A use a swab to collect a sample or specimen from the region of the throat suspected of being infected. Reagents are added to the head of the swab to form nitrous acid, typically sodium nitrite solution and a weak acid such as acetic acid. Nitrous acid acts on the Strep.A bacteria to release its 30 diagnostically specific antigen. This extraction of antigen may be "off board", for

example in a reaction cup provided with the test, or "onboard", with the swab inserted into a receptacle in the housing of the test. Typically, an extraction time of 1 minute is allowed for release of antigen before commencement of the test.

5 Figure 1(a) is an exploded drawing showing the general construction of the housing of the testing device of this embodiment of the invention, while

Figure 1(b) shows the assembled housing.

10 In this embodiment, the housing comprises a base (11) which is preferably made of a plastic that may be vacuum or pressure formed to provide a recess or cavity (12), as illustrated. A cover (13), preferably made of plastic or other waterproof material and provided with two openings (14) and (15) is sealed to the base (11), but not the recess (12), by adhesive or other sealing or aperture means. A plastic cover strip (16) is sealed to the cover (13), as illustrated so that the aperture (15) is covered, but with the strip remaining open along one edge (17). The shaded areas (18) on the cover strip (16) represent the sealing or glue pattern.

20 Figure 1(c) shows the assembled housing with a swab (19) inserted in the recess (12) and immunodiagnostic test strip (20) inserted under the plastic cover strip (16).

Figure 2 illustrates the generalised construction of an immunodiagnostic test strip suitable for use with this testing device.

25

When the swab (10) is fully inserted into the recess (12) in the housing via the aperture (14), its head (which contains the sample or specimen) is exposed in the other aperture (15). The addition of extraction reagents to the recess, for example via aperture (14), enables reagent to accumulate in the head of the swab, thereby 30 releasing any Strep.A antigen that may be present. After allowing time for this

extraction, the test strip (20) is inserted under the cover strip (16) so that it makes liquid-conductive contact with the head of the swab at the origin of the test strip. Liquid migrates from the swab to the test strip, thereby developing the test result in the test strip.

5

In a further development of this embodiment of the testing device, the extraction reagents, or other reagents required in other test formats, may be blister packed within the housing so that the insertion of the swab bursts the blister packaging to the reagents.

10

In addition, some tests for pathogens (e.g. Strep.B, some pathogenic *E. coli*) require a period of culture to increase the concentration of the organism before testing. In this format, liquid culture medium may be added (or issued pre-packed) to the housing prior to insertion of the swab or other sample collection device in order to allow 15 "onboard" culturing.

For specimens that require a specified volume of reagent, e.g. for semi-quantitative or quantitative assays, a specifically designed sample collection device may be used instead of a swab as described above. It is anticipated that the same 20 generic housing illustrated above would be used with such a semi-quantitative or quantitative sample collection device.

A preferred embodiment of such a collection device is illustrated in Figure 3, and comprises a plastic handle (21), (e.g. of polystyrene or similar plastic) which has 25 laminated thereto a hydrophilic matrix of defined absorptive volume (22). Suitable matrix materials include porous plastic, paper, non-woven synthetic fabrics, fibreglass, etc. Porous plastics made by Porex (Fairburn, GA, USA) of high molecular weight polyethylene have been found to be particularly suitable. This collection device has the advantage that it may be manufactured inexpensively by established industrial 30 web-handling, laminating and die-cutting processes.

In use, the matrix of the collection device is touched to the liquid to be sampled until it has absorbed its predetermined fill volume of sample. The collection device is then inserted into the recess in the housing and the test completed by insertion of the immunodiagnostic test strip as described above.

5 Persons skilled in the art will recognise that many modifications or variations may be made to the devices described in detail herein in order to suit other testing purposes or by way of adaptation for optimal function, without departing from the spirit and scope of the present invention as broadly described above.

PCT/AU00/00180

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A device for use in the collection and testing of a sample, comprising:
 - a. a housing having an internal recess; and
 - b. a sample collection device;

said housing being adapted to receive said sample collection device in the internal recess therein and to shield a sample collected on said sample collection device, said housing also being adapted to receive an insertable testing element such that, on insertion of said testing element into said housing, the testing element is in liquid-conductive communication with a sample collected on said sample collection device.
2. A testing device for the identification of an analyte of interest in a sample, comprising:
 - a. a housing having an internal recess;
 - b. a sample collection device; and
 - c. at least one insertable testing element;

said housing being adapted to receive said sample collection device in the internal recess therein and to shield a sample collected on said sample collection device, said housing also being adapted to receive the or each said insertable testing element such that, on insertion of said testing element into said housing, the testing element is in liquid-conductive communication with a sample collected on said sample collection device.
3. A device according to claim 1 or claim 2, wherein, on insertion of the testing element into the housing, the testing element is in direct liquid-conductive communication with a sample collected on the sample collection device.
4. A device according to claim 1 or claim 2, wherein the sample collection device is a swab.

- 20 -

5. A device according to claim 1 or claim 2, wherein the sample collection device collects a predetermined amount of the sample.
6. A device according to claim 5, wherein the sample collection device comprises a hydrophilic, porous matrix of defined volumetric capacity, affixed to the base of a dipstick or handle.
7. A device according to claim 1 or claim 2, wherein the housing is provided with a first window or aperture communicating with the internal recess within the housing for insertion of the sample collection device, together with a least one additional window or aperture which is separate from the first window or aperture and which also communicates with the internal recess for insertion of the, or each, insertable testing element so that the testing element is in liquid-conductive communication with a sample collected on said sample collection device.
8. A device according to claim 2, wherein the insertable testing element is a guaiac-based test strip.
9. A device according to claim 2, wherein the insertable testing element is an immunochromatographic test strip.
10. A device according to claim 2, which comprises two or more insertable testing elements each of which, when inserted into the housing, is in liquid-conductive communication with a sample collected on the sample collection device.
11. A device according to claim 10, wherein the testing elements are the same elements.

12. A device according to claim 10, wherein the testing elements are different elements.
13. A device according to claim 10, wherein at least one of said testing elements is an immunochromatographic test strip.
14. A device according to claim 10, wherein at least one of said testing elements is a guaiac-based test strip.
15. A device according to claim 1 or claim 2, wherein the housing is provided with a solvent application aperture in communication with the internal recess.
16. A method for the identification of an analyte of interest in a sample, using a device according to claim 1 or claim 2 comprising:
 - a. collecting a sample on the sample collection device,
 - b. inserting said sample collection device into the internal recess of the housing of the device, and
 - c. inserting the insertable testing element into the housing such that the testing element is in liquid-conductive communication with said sample.
17. A method according to claim 16, further comprising:
 - d. applying a solvent to said sample to enable transfer of at least part of said sample, or a component thereof, to the testing element.

1 / 2




FIG 1(b)






FIG 1(c)

2 / 2

**FIG 2****FIG 3**

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled SAMPLE COLLECTION AND TESTING SYSTEM, the specification of which:

is attached hereto.
 was filed on September 12, 2001 as Application Serial No. 09/936,452 and was amended on _____
 was described and claimed in PCT International Application No. _____ filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
Australia	PP 9157/99	March 11, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
PCT	PCT/AU00/00180	March 10, 2000	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Janis K. Fraser, Ph.D., J.D., Reg. No. 34,819
Timothy A. French, Reg. No. 30,175
Ralph A. Mittelberger, Reg. No. 33,195

John W. Freeman, Reg. No. 29,066
Anita L. Meiklejohn, Ph.D., Reg. No. 35,283
J. Peter Fasse, Reg. No. 32,983

Address all telephone calls to JANIS K. FRASER, PH.D., J.D. at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER, PH.D., J.D. at:

FISH & RICHARDSON P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Combined Declaration and Power of Attorney

Page 2 of 2 Pages

Full Name of Inventor: HOWARD MILNE CHANDLER

Inventor's Signature: H. M. Chandler

Date: November 15, 2001

Residence Address: Yarmouth, ME 04096

ME

Citizenship: Australia

Post Office Address: 857 Princes Point Road, Yarmouth, ME 04096

Full Name of Inventor: LAWRENCE CHARLES LA POINTE

Inventor's Signature: L. C. La Pointe

Date: November 15, 2001

Residence Address: New South Wales, Australia

AUS

Citizenship: United States

Post Office Address: 67-143 Kurraba Road, Neutral Bay, New South Wales 2089 Australia

20338306.doc

Applicant or Patentee: Howard M. Chandler Attorney's Dkt. No 13521-002001
 Serial or Patent No.: 09/936,452
 Filed or Issued: September 12, 2001
 For: SAMPLE COLLECTION AND TESTING SYSTEM

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS [37 19(f) and 1.27(c)] - SMALL BUSINESS CONCERN**

I hereby declare that I am

the owner of the small business concern identified below.
 an official of the small business concern empowered to act on behalf of the concern identified below:
 NAME OF CONCERN ENTERIX INC.

hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 5, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the 12 periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled:

Sample collection and testing system

Inventors Howard Milne CHANDLER, Lawrence Charles LA POINTE described in
 the specification filed herewith. (x) Filed as International Patent Application PCT/AU00/00180
 application Serial No. _____, filed _____,
 patent No. _____, issued _____

The rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

Name _____
 Address _____
 Individual Small Business Concern Nonprofit Organization

Name _____
 Address _____
 Individual Small Business Concern Nonprofit Organization

I acknowledge the duty to file, in this application of patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Howard Milne Chandler
 NAME OF PERSON OTHER THAN OWNER CEO & President
 ADDRESS OF PERSON SIGNING 857 Prince Point Rd, Falmouth, Maine 04046
 DATE 9/25/01
 SIGNATURE H. M. Chandler